Updates on OPT - Any holders around, page-12

If you are referring to the Bioshares Coference it doesn`t happen until the 29th - 30th July.
However words attributed to Megan Baldwin already posted by yehudi show that she is very confident of a positive outcome. Here are the words again

"New data shows VEGF-C protein levels have been found to increase by 66% when patients take a VEGF-A inhibitor, supporting the idea that blocking the VEGF-C pathway as well will improve patient outcomes.
When Megan Baldwin was questioned as to why the company has not released some of the data from the current open label Phase Ib study her response was that there is generally a strong improvement after the first month of therapy, so the company wanted to provide full three month treatment data from the trial."

VEGF-A is the target for Opthotech capped at $2+billion, what does that make OPT worth after even a successful phase 1??

http://www.nasdaq.com/symbol/opht